1 Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital, Nordsjælland, Hillerød 3400, Denmark; Department of Bacteria, Parasites, and Fungi, Statens Serum Institute, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark; European Society of Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG), Basel, Switzerland. Electronic address: zitta.barrella.harboe@regionh.dk.
2 Department of Medicine, School of Medicine, University of Seville, Seville, Spain; Clinical Unit of Infectious Diseases and Microbiology, Virgen del Rocío University Hospital, Seville, Spain; Institute of Biomedicine of Seville (IBiS), CIBER in Infectious Diseases, Seville, Spain; European Society of Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH), Basel, Switzerland.
3 European Society of Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH), Basel, Switzerland; Department of Infectious Diseases, Prince of Wales Hospital, Sydney, NSW, Australia.
4 European Society of Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG), Basel, Switzerland; Leiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, Netherlands.
5 European Society of Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG), Basel, Switzerland; Infectious Diseases, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique, CIC, 1406, Inserm-CHUGA-UGA, Grenoble, France.
6 European Society of Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH), Basel, Switzerland; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands.